allogeneic variable delta 1 gamma-delta t-lymphocytes gdx012
Generic: Allogeneic Variable Delta 1 Gamma-delta T-lymphocytes GDX012
allogeneic variable delta 1 gamma-delta t-lymphocytes gdx012: 1 clinical trial tracked.
allogeneic variable delta 1 gamma-delta t-lymphocytes gdx012 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about allogeneic variable delta 1 gamma-delta t-lymphocytes gdx012, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1/2a, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety and Efficacy of GDX012 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Primary endpoint: Number of Participants With Dose Limiting Toxicities (DLTs)
Interventionalopen16 targetStarted 2023-07Completion 2025-1111 sites · Japan, United StatesTakeda